Influence of dietary lysine on growth performance of high-lean growth gilts fed from 160 to 300 lb

One-hundred eight high-lean growth gilts (159.6 lb) were used to determine the dietary lysine requirement to optimize growth performance from 160 to 300 lb. The experiment was designed as a randomized complete block, with initial weight serving as the blocking factor. Six dietary treatments were used, ranging from .44 to .94% digestible lysine (.59 to 1.16% total lysine). Pigs were housed in pens of three, with six replicate pens/treatment. Pig weights and feed disappearance were collected weekly to calculate average daily gain (ADG), average daily feed intake (ADFI), and feed efficiency (F/G). Average daily gain increased from 160 to 230 lb, from 230 to 300 lb, and from 160 to 300 lb. Average daily feed intake was not influenced by dietary treatment. The gilts consumed 6.47, 6.65, and 6.56 lb/day from 160 to 230, from 230 to 300, and from 160 to 300 lb, respectively. Thus, F/G improved linearly from 160 to 230 lb and quadratically from 230 to 300 and from 160 to 300 lb as a function of increased ADG. Lysine intake was increased linearly for all three weight periods as digestible lysine increased in the diet. The data from this experiment suggest that high-lean growth gilts requires at least 26 g/d of lysine from 160 to 230 and from 230 to 300 lb. Thus, matching nutrition with genetics is essential to optimize both rate and efficiency of gain

Effectiveness and tolerability of 12-Month Brivaracetam in the real world: EXPERIENCE, an international pooled analysis of individual patient records

Background and Objective Real-world evidence studies of brivaracetam (BRV) have been restricted in scope, location, and patient numbers. The objective of this pooled analysis was to assess effectiveness and tolerability of brivaracetam (BRV) in routine practice in a large international population. Methods EXPERIENCE/EPD332 was a pooled analysis of individual patient records from multiple independent non-interventional studies of patients with epilepsy initiating BRV in Australia, Europe, and the United States. Eligible study cohorts were identified via a literature review and engagement with country lead investigators, clinical experts, and local UCB Pharma scientific/medical teams. Included patients initiated BRV no earlier than January 2016 and no later than December 2019, and had ≥ 6 months of follow-up data. The databases for each cohort were reformatted and standardised to ensure information collected was consistent. Outcomes included ≥ 50% reduction from baseline in seizure frequency, seizure freedom (no seizures within 3 months before timepoint), continuous seizure freedom (no seizures from baseline), BRV discontinuation, and treatment-emergent adverse events (TEAEs) at 3, 6, and 12 months. Patients with missing data after BRV discontinuation were considered non-responders/not seizure free. Analyses were performed for all adult patients (≥ 16 years), and for subgroups by seizure type recorded at baseline; by number of prior antiseizure medications (ASMs) at index; by use of BRV as monotherapy versus polytherapy at index; for patients who switched from levetiracetam to BRV versus patients who switched from other ASMs to BRV; and for patients with focal-onset seizures and a BRV dose of ≤ 200 mg/day used as add-on at index. Analysis populations included the full analysis set (FAS; all patients who received at least one BRV dose and had seizure type and age documented at baseline) and the modified FAS (all FAS patients who had at least one seizure recorded during baseline). The FAS was used for all outcomes other than ≥ 50% seizure reduction. All outcomes were summarised using descriptive statistics. Results Analyses included 1644 adults. At baseline, 72.0% were 16–49 years of age and 92.2% had focal-onset seizures. Patients had a median (Q1, Q3) of 5.0 (2.0, 8.0) prior antiseizure medications at index. At 3, 6, and 12 months, respectively, ≥ 50% seizure reduction was achieved by 32.1% (n = 619), 36.7% (n = 867), and 36.9% (n = 822) of patients; seizure freedom rates were 22.4% (n = 923), 17.9% (n = 1165), and 14.9% (n = 1111); and continuous seizure freedom rates were 22.4% (n = 923), 15.7% (n = 1165), and 11.7% (n = 1111). During the whole study follow-up, 551/1639 (33.6%) patients discontinued BRV. TEAEs since prior visit were reported in 25.6% (n = 1542), 14.2% (n = 1376), and 9.3% (n = 1232) of patients at 3, 6, and 12 months, respectively. Conclusions This pooled analysis using data from a variety of real-world settings suggests BRV is effective and well tolerated in routine clinical practice in a highly drug-resistant patient population

Influence of dietary lysine on carcass characteristics of high-lean growth gilts fed from 80 to 160 lb

Seventy-two high-lean growth gilts (initially 75.5 lb BW) were used to determine the influence of dietary lysine on carcass characteristics at 120 and 160 lb. Gilts were randomly selected for slaughter when the average weight of pigs in the pen equaled or exceeded 120 and 160 lb. The experiment was designed as a randomized complete block, with initial weight serving as the blocking factor. Six dietary treatments were included, ranging from .54 to 1.04% digestible lysine (.69 to 1.25% total dietary lysine). At 120 lb, hot carcass weight decreased and then increased as did dressing percentage for gilts fed increased dietary lysine. Average backfat thickness and 10th rib fat depth were not influenced by dietary treatment. However, longissimus muscle area (loineye) was increased for gilts fed greater dietary lysine. Kidney fat and total carcass lipid decreased but carcass moisture increased as dietary lysine increased. The decreased carcass lipid content resulted in reduced longissimus muscle marbling at 120 lb. For gilts fed to 160 lb, hot and chilled carcass weight decreased and then increased as dietary lysine increased. Dressing percentage followed a similar pattern because of the difference in carcass weight. Backfat thickness, 10th rib fat thickness, and kidney fat decreased for gilts fed increased dietary lysine. Carcass moisture and crude protein increased and then decreased as dietary lysine increased. The moisture content was maximal for gilts fed .94% digestible lysine, whereas carcass crude protein was maximal for gilts fed .74% digestible lysine. However, carcass lipid followed an opposite pattern, decreasing and then increasing as dietary lysine increased. Carcass muscle score improved but longissimus muscle marbling decreased for gilts fed greater dietary lysine. The data from this experiment suggest that the high-lean growth gilt requires at least 18 and 22 g/d lysine intakes from 80 to 120 and from 120 to 160 lb, respectively, to optimize longissimus muscle area and minimize carcass lipid content

Influence of dietary lysine on growth performance and tissue accretion rates of high-lean growth gilts fed from 80 to 160 lb

One-hundred eight high-lean growth gilts (75.5 lb initial weight) were used to determine the dietary lysine requirement to maximize growth performance and protein accretion from 80 to 160 lb. The experiment was designed as a randomized complete block, with initial weight serving as the blocking factor. Six dietary treatments were included, ranging from .54 to 1.04% digestible lysine (.69 to 1.25% total dietary lysine). Pigs were housed in pens of three, with six replicate pens/treatment. Pig weights and feed disappearance were collected weekly to calculate average daily gain (ADG), average daily feed intake ADFI, and feed efficiency (F/G). Initially, six pigs were slaughtered to determine baseline carcass composition. When the mean weight for pigs in a pen reached 120 and 160 lb, one pig per pen was randomly selected and slaughtered for carcass analyses. The right side of each carcass was ground twice and sampled to determine carcass composition and lean tissue (crude protein) accretion rate. Average daily gains were greater for gilts fed increased dietary lysine from 80 to 120 lb, from 120 to 160 lb, and from 80 to 160 lb. Average daily feed intakes from 80 to 120 and from 120 to 160 lb were not influenced by dietary lysine. However, ADFI for the entire experiment tended to decrease as digestible lysine increased. Increased dietary lysine resulted in improved F/G from 80 to 120 lb and from 120 to 160 and 80 to 160 lb. Gilts fed increased digestible lysine had greater CP accretion from 80 to 120 lb, 120 to 160 lb, and 80 to 160 lb . Based on the feed intake observed in this study, the highlean growth gilt requires at least 18 to 19 and 22 g/d lysine intakes from 80 to 120 lb and from 120 to 160 lb, respectively, to maximize ADG, F/G, and lean accretion

Heart rate variability dynamics during treatment for exertional heat strain when immediate response is not possible

New Findings: What is the central question of this study? Does a delay in cold water immersion treatment affect the cardiac autonomic control of exertionally heat-strained individuals? What is the main finding and its importance? Cold water immersion is effective for treating exertionally heat-strained individuals even when treatment is commenced with a significant delay. However, that treatment delay leads to only partial/transient restoration of cardiac autonomic control. Therefore, we recommend that exertional heatstroke patients are continuously monitored for several hours even after core temperature has returned to normal values. Abstract: Immediate cold water immersion (CWI) is the gold-standard treatment for exertional heatstroke. In the field, however, treatment is often delayed, primarily owing to a delayed paramedic response and/or inaccurate diagnosis. We examined the effect of treatment (reduction of rectal temperature to 37.5°C) delays of 5 (short), 20 (moderate) and 40 (prolonged) min on cardiac autonomic control [as assessed via heart rate variability (HRV)] in eight exertionally heat-strained (40.0°C rectal temperature) individuals. Eleven HRV indices were computed that have been described commonly in the literature and characterize almost all known domains of the variability and complexity of the cardiopulmonary system. We found that the cardiac autonomic control (as assessed via HRV) of exertionally heat-strained individuals was significantly affected by the amount of time it took for the CWI treatment to be applied. Six out of 11 HRV indices studied, from all variability domains, displayed strong (P ≤ 0.005) time × delay interaction effects. Moreover, the number of significantly (P ≤ 0.005) abnormal (i.e. different from the short delay) HRV indices more than doubled (seven versus 15) from the moderate delay to the prolonged delay. Finally, our results demonstrated that a CWI treatment applied with delays of 20 and, primarily, 40 min did not lead to a full restoration of cardiac autonomic control of exertionally heat-strained individuals. In conclusion, this study supports CWI for treating exertionally heat-strained individuals even when applied with prolonged delay, but it highlights the importance of continued cardiac monitoring of patients who have suffered exertional heatstroke for several hours after restoration of core temperature to normal. © 2019 The Authors. Experimental Physiology © 2019 The Physiological Societ